- Home
- GPRK vs MREO Comparison
GPRK vs MREO Comparison
Compare GPRK & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPRK | MREO |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | Colombia | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.8M | 324.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GPRK | MREO |
|---|---|---|
| Price | $8.12 | $0.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $8.50 | $3.90 |
| AVG Volume (30 Days) | 548.8K | ★ 38.5M |
| Earning Date | 02-25-2026 | 11-10-2025 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $525,938,000.00 | $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6,363.05 |
| P/E Ratio | $11.89 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.66 | $0.20 |
| 52 Week High | $10.13 | $3.26 |
Technical Indicators
Market Signals| Indicator | GPRK | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 63.97 | 33.01 |
| Support Level | $7.40 | $0.48 |
| Resistance Level | $7.70 | $0.78 |
| Average True Range (ATR) | 0.27 | 0.10 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 96.29 | 41.18 |
Price Performance
Historical ComparisonAbout GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).